{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T18:16:00Z","timestamp":1783361760624,"version":"3.54.6"},"reference-count":21,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Psoriatic arthritis (PsA) is a heterogeneous, chronic inflammatory disease with diverse musculoskeletal and extra-articular manifestations, including enthesitis and dactylitis, which contribute substantially to disease burden, disability, and poor quality of life. Therapeutic advances have mainly focused on polyarticular disease, with limited representation of other PsA domains and real-world complexity. The Observational Best Practices Research Initiative for Psoriatic Arthritis (OBRI-PsA) was established as a national registry to systematically capture diverse PsA phenotypes, assess real-world treatment patterns, and longitudinal clinical outcomes. This report describes the registry methodology and presents preliminary findings from the initial enrolled cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>OBRI-PsA is actively enrolling patients with active PsA initiating new disease-modifying therapy, irrespective of domain or burden. Baseline and follow-up data are systematically collected to evaluate treatment responses, patient-reported outcomes, productivity, and real-world strategies. Descriptive analyses of 18-month outcomes from the first 101 enrolled patients are presented as a proof-of-concept; the full study protocol is available in the supplementary material.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>As of September 2024, a total of 101 patients were enrolled (mean age 53.9\u2009\u00b1\u200912.7 years; 61.4% female). Symmetrical polyarthritis predominated (86.1%), with 91% having skin psoriasis, 49% enthesitis, and 42% dactylitis. At baseline, mean tender and swollen joint counts were 9.8 and 6.5. Over 18 months, patient- and physician-reported outcomes improved, yet only one-third achieved minimal disease activity (MDA). Response rates varied across domains, with the lowest rate observed for enthesitis (24%). Most patients (60\u201374%) remained on the same therapy at follow-up with no further modifications, despite ongoing disease activity. Patients with fibromyalgia reported higher disease activity, lower quality of life, and fewer treatment responses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Preliminary data from OBRI-PsA highlight persistent unmet needs and variable treatment responses across PsA phenotypes in real-world practice, with relatively few patients achieving treatment targets. These early signals underscore the importance of a comprehensive, longitudinal registry platform to better characterize disease heterogeneity and to inform future phenotype-driven, outcome-focused analyses.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0352264","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T17:33:07Z","timestamp":1783359187000},"page":"e0352264","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Improving outcomes of patients living with psoriatic arthritis: The Observational Best Practices Research Initiative (OBRI-PsA) registry: Rationale, Methodology and Preliminary Data of 18 Months Follow-up"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-1165-1173","authenticated-orcid":true,"given":"Rahaf Zyad","family":"Attar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Movahedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Cesta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Sabido-Sauri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozun Bayindir","family":"Tsechelidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carter","family":"Thorne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Haaland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Soucy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Bombardier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibel Zehra","family":"Aydin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"OBRI Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"issue":"1","key":"pone.0352264.ref001","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.semarthrit.2018.01.003","article-title":"Prevalence and incidence of psoriatic arthritis: a systematic review and meta-analysis","volume":"48","author":"L Scotti","year":"2018","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"pone.0352264.ref002","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jaad.2005.03.046","article-title":"Epidemiology of psoriatic arthritis in the population of the United States","volume":"53","author":"JM Gelfand","year":"2005","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"pone.0352264.ref003","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s12016-017-8630-7","article-title":"Clinical features of psoriatic arthritis: a comprehensive review of unmet clinical needs","volume":"55","author":"A McArdle","year":"2017","journal-title":"Clinic Rev Allerg Immunol"},{"issue":"1","key":"pone.0352264.ref004","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0049-0172(73)90035-8","article-title":"Psoriatic arthritis","volume":"3","author":"JM Moll","year":"1973","journal-title":"Semin Arthritis Rheum"},{"issue":"10","key":"pone.0352264.ref005","first-page":"446","article-title":"Proposed classification criteria of psoriatic arthritis. A preliminary study in 260 patients","volume":"66","author":"B Fourni\u00e9","year":"1999","journal-title":"Rev Rhum Engl Ed"},{"issue":"6","key":"pone.0352264.ref006","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1002\/1529-0131(199906)42:6<1080::AID-ANR2>3.0.CO;2-7","article-title":"Psoriatic arthritis: a unified concept twenty years on","volume":"42","author":"D McGonagle","year":"1999","journal-title":"Arthritis Rheum"},{"issue":"8","key":"pone.0352264.ref007","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: development of new criteria from a large international study","volume":"54","author":"W Taylor","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"3","key":"pone.0352264.ref008","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.semarthrit.2017.05.010","article-title":"The psychosocial burden of psoriatic arthritis","volume":"47","author":"ME Husni","year":"2017","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"pone.0352264.ref009","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/1529-0131(199806)41:6<1103::AID-ART18>3.0.CO;2-N","article-title":"Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death","volume":"41","author":"DD Gladman","year":"1998","journal-title":"Arthritis Rheum"},{"issue":"3","key":"pone.0352264.ref010","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.berh.2019.03.001","article-title":"Opportunities and challenges in the treatment of psoriatic arthritis","volume":"32","author":"O FitzGerald","year":"2018","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"1","key":"pone.0352264.ref011","article-title":"What does evidence-based medicine tell us about treatments for different subtypes of psoriatic arthritis? A systematic literature review on randomized controlled trials","volume":"2","author":"S Bakirci Ureyen","year":"2018","journal-title":"Rheumatol Adv Pract"},{"issue":"5","key":"pone.0352264.ref012","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1080\/03009740902842190","article-title":"Potential effects of a national consensus statement on optimal treatment of early rheumatoid arthritis in Ontario","volume":"38","author":"S Bernatsky","year":"2009","journal-title":"Scand J Rheumatol"},{"issue":"3","key":"pone.0352264.ref013","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.semarthrit.2016.08.012","article-title":"2016 Revisions to the 2010\/2011 fibromyalgia diagnostic criteria","volume":"46","author":"F Wolfe","year":"2016","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"pone.0352264.ref014","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/rheumatology\/keaa663","article-title":"PsART-ID inception cohort: clinical characteristics, treatment choices and outcomes of patients with psoriatic arthritis","volume":"60","author":"G Ayan","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"pone.0352264.ref015","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.3899\/jrheum.171406","article-title":"Influence of disease manifestations on health-related quality of life in early psoriatic arthritis","volume":"45","author":"K Wervers","year":"2018","journal-title":"J Rheumatol"},{"issue":"1","key":"pone.0352264.ref016","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000638","article-title":"Baseline patient characteristics associated with response to biologic therapy in patients with psoriatic arthritis enrolled in the Corrona Psoriatic Arthritis\/Spondyloarthritis Registry","volume":"4","author":"PJ Mease","year":"2018","journal-title":"RMD Open"},{"issue":"12","key":"pone.0352264.ref017","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.3899\/jrheum.210434","article-title":"Oligoarticular vs polyarticular psoriatic arthritis: a longitudinal study showing similar characteristics","volume":"48","author":"DD Gladman","year":"2021","journal-title":"J Rheumatol"},{"issue":"2","key":"pone.0352264.ref018","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1093\/rheumatology\/kew375","article-title":"The psoriatic arthritis registry of Turkey: results of a multicentre registry on 1081 patients","volume":"56","author":"U Kalyoncu","year":"2017","journal-title":"Rheumatology"},{"issue":"9","key":"pone.0352264.ref019","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1111\/1756-185X.14805","article-title":"Chinese Registry of Psoriatic Arthritis (CREPAR): I. Clinical characteristics of Chinese patients with psoriatic arthritis","volume":"26","author":"C Lu","year":"2023","journal-title":"Int J Rheum Dis"},{"issue":"2","key":"pone.0352264.ref020","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/1756-185X.13987","article-title":"Fibromyalgia in patients with psoriatic arthritis: Impact on disease activity indices, fatigue and health-related quality of life","volume":"24","author":"NA Elsawy","year":"2021","journal-title":"Int J Rheum Dis"},{"issue":"2","key":"pone.0352264.ref021","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/1756-185X.13963","article-title":"Fibromyalgia in patients with psoriatic arthritis: Relationship with enthesopathy, sleep, fatigue and quality of life","volume":"24","author":"F Ulutatar","year":"2021","journal-title":"Int J Rheum Dis"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0352264","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T17:33:12Z","timestamp":1783359192000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0352264"}},"subtitle":[],"editor":[{"given":"Wesam","family":"Gouda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":21,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7,6]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0352264","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]}}}